ReviewOncotarget2018
Prostaglandins in the pathogenesis of kidney diseases.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Treprostinil reduces blood pressure and aortic inflammation in hypertension.Clinical science (London, England : 1979) · 2026Article
- Morin ameliorates lipopolysaccharide-induced acute kidney injury in rats via alteration of TLR4/NF-κB, COX-2/PGE2, and monocyte chemoattractant protein-1/CXCL1 signaling pathway.Indian journal of pharmacology · 2026Article
- The dual pathological roles and targeted therapy of PGEFrontiers in pharmacology · 2026Review
- Cytoprotective effect of prostacyclin on hepatic ischemia-reperfusion injury.World journal of methodology · 2025Review
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV-2 Infection.Kidney360 · 2025Article
- Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation.Journal of clinical medicine · 2025Review
- U-TXM: a novel biomarker for early detection of diabetic kidney disease.Frontiers in endocrinology · 2025Article
- Metabolomic analysis of fatal hypothermia using ultra-high-performance liquid chromatography‒mass spectrometry.Frontiers in molecular biosciences · 2025Article
- Advances in PGD2/PTGDR2 signaling pathway in tumors: A review.Biomolecules & biomedicine · 2024Review
- Effects of ultra-processed foods on the liver: insights from gut microbiome and metabolomics studies in rats.Frontiers in nutrition · 2024Article
- Defining the molecular fingerprint of bladder and kidney fibroblasts.American journal of physiology. Renal physiology · 2023Review
- The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease.Journal of translational medicine · 2023Review
- Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis.Physiological reviews · 2023Review
- The Role of Gender Differences and Menopause in Obesity-Related Renal Disease, Renal Inflammation and Lipotoxicity.International journal of molecular sciences · 2023Article
- Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy.Journal of translational medicine · 2023Article
- The association of urinary prostaglandins with uric acid in hyperuricemia patients.BMC nephrology · 2022Article
- Review
- Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions.Scientific reports · 2022Article
- Agonists of prostaglandin EProceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostaglandins (PGs) are important lipid mediators produced from arachidonic acid via the sequential catalyzation of cyclooxygenases (COXs) and specific prostaglandin synthases. There are five subtypes of PGs, namely PGE2, PGI2, PGD2, PGF2α, and thromboxane A2 (TXA2). PGs exert distinct roles by combining to a diverse family of membrane-spanning G protein-coupled prostanoid receptors. The distribution of these PGs, their specific synthases and receptors vary a lot in the kidney. This review summarized the recent findings of PGs together with the COXs and their specific synthases and receptors in regulating renal function and highlighted the insights into their roles in the pathogenesis of various kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.